Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome. Oyarbide U, Bezzerri V, Staton M, Boni C, et al. J Clin Invest 2025;135:e187778.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Oyarbide U, Bezzerri V, Staton M, Boni C, et al. Reduced EIF6 dosage attenuates TP53 activation in models of Shwachman-Diamond syndrome. J Clin Invest 2025;135:e187778.
PMID: 39964763